Other Events ·
FDA lifts clinical hold on AB-101 IND for oral PD-L1 inhibitor
ABUSArbutus Biopharma Corp
The U.S. Food and Drug Administration has lifted the clinical hold on Arbutus Biopharma's Investigational New Drug application for AB-101, an oral PD-L1 inhibitor. The company may now engage in additional clinical development for the candidate in the United States. AB-101 is designed to activate patients' hepatitis B virus-specific immune response and has shown high receptor occupancy in Phase 1a/1b trials. Arbutus Biopharma Corporation operates as a clinical-stage biopharmaceutical company focused on infectious disease.